The total number of records retrieved from this search are 84. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_862	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_865	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result96% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_868	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_871	Virus nameHerpes simplex virus	Virus strainBL1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_874	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result85 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_877	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result97% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_880	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60 % cancerous cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_883	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal adenocarcinoma cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result88% cancerous cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12595888
IDOV_1094	Virus nameAdenovirus	Virus strainZD55-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing ZD55 gene and IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineHT-29	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1095	Virus nameAdenovirus	Virus strainAd-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineHT-29	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result20% cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1096	Virus nameAdenovirus	Virus strainZD55-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing EGFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman cervical carcinoma cell line	Cell lineHT-29	Concentration of cell line2.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result40% cell killing after 80 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1155	Virus nameHerpes simplex virus	Virus strainNV1020	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon carcinoma cell line	Cell lineHT-29	Concentration of cell line2.5E+3 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 × 10⁶ pfu/ml	In-vitro result80% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17117895
IDOV_1158	Virus nameHerpes simplex virus	Virus strainNV1020	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FU	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon carcinoma cell line	Cell lineHT-29	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 × 10⁶ pfu/ml	In-vitro resultComplete reduction in tumor,shows synergism with drug	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17117895
IDOV_1159	Virus nameHerpes simplex virus	Virus strainNV1020	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with SN-38	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon carcinoma cell line	Cell lineHT-29	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 × 10⁶ pfu/ml	In-vitro resultComplete reduction in tumor,shows synergism with drug	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17117895
IDOV_2144	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 12	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2145	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 15	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2146	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 17	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 1 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2147	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 26	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2148	Virus nameEnterovirus	Virus strainEnterovirus B species echovirus 29	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMicroscopy examination	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus can cause induction in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21999585
IDOV_2764	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2765	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2766	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2767	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2813	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2814	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2815	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2828	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2829	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2830	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2849	Virus nameMeasles virus	Virus strainAttenuated strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayCell death detection kit	In-vitro virus concentration1 MOI	In-vitro result45% cells survived	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of caspase-3	Immunogenic effectNA	Clinical trialNA	PMID23586034
IDOV_2992	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2993	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2994	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2995	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2996	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result20% cell survival after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2997	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2998	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2999	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3000	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3001	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3003	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (5.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reached 1500mm after day 50	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3005	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HT-29 (3.0E+9 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 300mm after 45 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3594	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result98% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3595	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result85% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3596	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result98% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3597	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result98% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3598	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result98% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3599	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3600	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3601	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3602	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result98% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3603	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3604	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3605	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result60% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3606	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3607	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3608	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3609	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3610	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3611	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3612	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3613	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3614	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3615	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3616	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3617	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (25 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration15 MOI	In-vitro result22% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3618	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for HT29 cell line (8.0E+6)	In-vivo virus concentration2.0E+9 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume to below 2000mm after 30 days comapred to control 4000mm	Mode of deliveryIntratumoral	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3673	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3674	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3689	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3690	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3705	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3706	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHT-29	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultComplete cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_4407	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration26.80+/- 7.82	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4408	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration74.23+/- 18.19	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4409	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration127.2+/- 39	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4410	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/CP-5c	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration7.56+/- 1.96	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4411	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/CP-5c	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration26.70+/- 5.90	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4412	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/CP-5c	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration49.95+/- 9.01	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4413	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/carbo-15d-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration20.13+/- 10.23	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4414	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/carbo-15d-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration48.46+/- 19.03	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4415	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon carcinoma	Cell lineHT-29/carbo-15d-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration78.27+/- 25.11	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_5625	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon carcinoma cell line	Cell lineHT-29	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 ×10⁶ pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5845	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon carcinoma cell line	Cell lineHT-29	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 ×10⁶ pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578